KANISA PHARMACEUTICALS INC has a total of 18 patent applications. Its first patent ever was published in 2006. It filed its patents most often in Canada, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals and measurement are JIANGXI XINGLIN BAIMA PHARMACEUTICAL CO LTD, LONGEVERON LLC and ANDRX LABS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 4 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Australia | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | China | 2 | |
#6 | Republic of Korea | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Hoth Daniel | 16 |
#2 | Walsh Michael J | 16 |
#3 | Multani Pratik S | 16 |
#4 | Marcelletti John | 16 |
#5 | Socks David | 16 |
#6 | Glenn Scott | 16 |
#7 | Sikic Branimir | 16 |
#8 | Schwegman Jeff | 3 |
#9 | Branimir Sikic | 2 |
#10 | Daniel Hoth | 2 |
Publication | Filing date | Title |
---|---|---|
AU2006269501A1 | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism | |
CN101257921A | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar | |
CA2630087A1 | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins | |
CN101252933A | ZOSUQUIDAR, daunorubicin, and cytarabine for the treatment of cancer | |
AU2006269492A1 | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer | |
AU2006269481A1 | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |